// App-Quantinova.ai

: Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients

Researchers

Presenter

  • Sushmitha Nanja Reddy

Principal Investigators

  • Abdul Moiz Khan

  • Vikram Dhillon

  • Ali Al Sbihi

  • Amanda Tear

  • Breanna William

  • Sonubar Virk

  • Julie Boerner

  • Suresh Kumar Balasubramanian

Medical Centers

  • Taussig Cancer Institute, Cleveland Clinic Foundation, Department of Translational Hematology and Oncology Research, Cleveland, OH

  • Department of Internal Medicine, Wayne State University, Detroit, MI

  • Department of Oncology, Wayne State University/ Karmanos Cancer Institute, Detroit, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Neurogenic locus notch homolog protein 2

  • Breakpoint Cluster Region

  • DNA methyltransferase 3 alpha

  • Fc gamma RIIIa

  • Tet methylcytosine dioxygenase 2

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Chromodomain-helicase-DNA-binding protein 4

  • Mitogen-Activated Protein Kinase Kinase Kinase 1

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved